Real-Life Effectiveness of Aclidinium/Formoterol on COPD Control: The REDACT Observational Study

Area of Science:

• Respiratory Medicine
• Pharmacology

Background:

• COPD control is crucial for managing patient status, influenced by clinical impact and stability.
• Limited data exist on the effectiveness of dual bronchodilation strategies for COPD control.

Purpose of the Study:

• To evaluate COPD control in patients with uncontrolled COPD after 12 weeks of treatment with aclidinium/formoterol.
• To assess changes in COPD Assessment Test (CAT) scores and forced expiratory volume in 1 second (FEV1).

Main Methods:

• A multicenter, prospective, longitudinal, real-life observational study (REDACT) was conducted.
• 1038 patients with uncontrolled COPD, not on triple therapy, received aclidinium/formoterol for 12 weeks.
• Primary endpoint was the proportion of patients achieving COPD control; secondary endpoints included changes in FEV1 and CAT scores.

Main Results:

• 83.7% of patients achieved COPD control after 12 weeks.
• Significant improvements were observed in FEV1 (124.8 mL) and CAT scores (-7.6 points).
• Predictors of lack of control included low baseline FEV1, prior exacerbations, and cardiovascular disease history.

Conclusions:

• Aclidinium/formoterol effectively improved COPD control in a significant proportion of patients within 12 weeks.
• The dual bronchodilator demonstrated significant benefits for lung function and health status.
• Real-world data support the use of aclidinium/formoterol for managing uncontrolled COPD.